These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Aspirin and other non-steroidal anti-inflammatory drugs for the prevention of dementia. Jordan F; Quinn TJ; McGuinness B; Passmore P; Kelly JP; Tudur Smith C; Murphy K; Devane D Cochrane Database Syst Rev; 2020 Apr; 4(4):CD011459. PubMed ID: 32352165 [TBL] [Abstract][Full Text] [Related]
23. Influence of microglia and astrocyte activation in the neuroinflammatory pathogenesis of Alzheimer's disease: Rational insights for the therapeutic approaches. Ahmad MH; Fatima M; Mondal AC J Clin Neurosci; 2019 Jan; 59():6-11. PubMed ID: 30385170 [TBL] [Abstract][Full Text] [Related]
24. Novel therapeutic opportunities for Alzheimer's disease: focus on nonsteroidal anti-inflammatory drugs. Townsend KP; Praticò D FASEB J; 2005 Oct; 19(12):1592-601. PubMed ID: 16195368 [TBL] [Abstract][Full Text] [Related]
25. Inhibitors of NF-κB and P2X7/NLRP3/Caspase 1 pathway in microglia: Novel therapeutic opportunities in neuroinflammation induced early-stage Alzheimer's disease. Thawkar BS; Kaur G J Neuroimmunol; 2019 Jan; 326():62-74. PubMed ID: 30502599 [TBL] [Abstract][Full Text] [Related]
26. The role of P2X7R in neuroinflammation and implications in Alzheimer's disease. Chen YH; Lin RR; Tao QQ Life Sci; 2021 Apr; 271():119187. PubMed ID: 33577858 [TBL] [Abstract][Full Text] [Related]
27. Non-steroidal anti-inflammatory drugs (NSAIDs) and other anti-inflammatory agents in the treatment of neurodegenerative disease. Klegeris A; McGeer PL Curr Alzheimer Res; 2005 Jul; 2(3):355-65. PubMed ID: 15974901 [TBL] [Abstract][Full Text] [Related]
28. Dystrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer's disease. Streit WJ; Braak H; Xue QS; Bechmann I Acta Neuropathol; 2009 Oct; 118(4):475-85. PubMed ID: 19513731 [TBL] [Abstract][Full Text] [Related]
29. Toxicity of the Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) acetylsalicylic acid, paracetamol, diclofenac, ibuprofen and naproxen towards freshwater invertebrates: A review. Parolini M Sci Total Environ; 2020 Oct; 740():140043. PubMed ID: 32559537 [TBL] [Abstract][Full Text] [Related]
30. Neuroinflammation and tumor necrosis factor signaling in the pathophysiology of Alzheimer's disease. McAlpine FE; Tansey MG J Inflamm Res; 2008; 1():29-39. PubMed ID: 22096345 [TBL] [Abstract][Full Text] [Related]
31. Are NSAIDs useful to treat Alzheimer's disease or mild cognitive impairment? Imbimbo BP; Solfrizzi V; Panza F Front Aging Neurosci; 2010; 2():. PubMed ID: 20725517 [TBL] [Abstract][Full Text] [Related]
32. Soothing the inflamed brain: effect of non-steroidal anti-inflammatory drugs on Alzheimer's disease pathology. Hoozemans JJ; Veerhuis R; Rozemuller JM; Eikelenboom P CNS Neurol Disord Drug Targets; 2011 Feb; 10(1):57-67. PubMed ID: 21143138 [TBL] [Abstract][Full Text] [Related]
33. [Nucleotide-binding Oligomerization Domain-like Receptor Family Pyrin Domain Containing 3 Inflammasome in Alzheimer's Disease]. Feng YY; Chen H Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2021 Oct; 43(5):788-795. PubMed ID: 34728041 [TBL] [Abstract][Full Text] [Related]
34. Use of nonsteroidal anti-inflammatory drugs and gastroprotective agents before the advent of cyclooxygenase-2-selective inhibitors: analysis of a large United States claims database. Schnitzer TJ; Kong SX; Mavros PP; Straus WL; Watson DJ Clin Ther; 2001 Dec; 23(12):1984-98. PubMed ID: 11813933 [TBL] [Abstract][Full Text] [Related]
35. The Role of NLRP3 Inflammasome in Alzheimer's Disease and Potential Therapeutic Targets. Liang T; Zhang Y; Wu S; Chen Q; Wang L Front Pharmacol; 2022; 13():845185. PubMed ID: 35250595 [TBL] [Abstract][Full Text] [Related]
36. Neuroinflammation in Alzheimer's disease: protector or promoter? Zilka N; Ferencik M; Hulin I Bratisl Lek Listy; 2006; 107(9-10):374-83. PubMed ID: 17262990 [TBL] [Abstract][Full Text] [Related]
37. Active immunization against complement factor C5a: a new therapeutic approach for Alzheimer's disease. Landlinger C; Oberleitner L; Gruber P; Noiges B; Yatsyk K; Santic R; Mandler M; Staffler G J Neuroinflammation; 2015 Aug; 12():150. PubMed ID: 26275910 [TBL] [Abstract][Full Text] [Related]
38. Alzheimer's disease, inflammation and non-steroidal anti-inflammatory drugs. Ferencik M; Novak M; Rovensky J; Rybar I Bratisl Lek Listy; 2001; 102(3):123-32. PubMed ID: 11433600 [TBL] [Abstract][Full Text] [Related]
39. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. McGettigan P; Henry D PLoS Med; 2011 Sep; 8(9):e1001098. PubMed ID: 21980265 [TBL] [Abstract][Full Text] [Related]
40. Microglia and Wnt Pathways: Prospects for Inflammation in Alzheimer's Disease. Yang Y; Zhang Z Front Aging Neurosci; 2020; 12():110. PubMed ID: 32477095 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]